A capsule-sponge test may help identify patients with Barrett’s esophagus who are at low risk for dysplasia or esophageal ...

OSWEGO – The Center for Gastroenterology & Metabolic Diseases of Oswego Health Medical Practice is now offering access to an innovative laboratory test — TissueCypher — that can help ...

In adult patients with nondysplastic Barrett esophagus at last endoscopy, a subsequent capsule-sponge test can assist in ...

Learn about the "pill-on-a-thread" that could replace endoscopies for half of all patients at risk of developing esophageal cancer.

Patients with low-grade dysplasia have around a one in 10 chance of developing esophageal cancer, but this risk doubles to one in five for high-grade dysplasia.

This cohort included 78 people with a normal esophagus, 77 with BE, 12 with high-grade dysplasia, five with low-grade dysplasia, one with indeterminate dysplasia and 61 with esophageal adenocarcinoma.

Castle Biosciences’ TissueCypher® test can offer patients with Barrett’s esophagus a clearer picture of their risk of developing esophageal cancer. Esophageal cancer is a killer. It’s the ...

Up to 25% of patients who end up developing high-grade dysplasia or esophageal cancer have progressed before their next endoscopy, representing missed opportunities for early intervention.

The annual incidence of cancer in women was 0.05% compared to 0.3% in men. The combined risk of high-grade dysplasia or esophageal cancer was also lower in women at 0.1% compared to 1.1% in men.

“While the benefit is clear for patients with high-grade dysplasia, we suggest considering endoscopic eradication therapy for patients with low-grade dysplasia after clearly discussing the risks ...

These cells can progress to dysplasia, which may eventually lead to cancer. Dysplasia is classified as low-grade or high-grade based on the extent of cellular changes.